ID | 47019 |
フルテキストURL | |
著者 |
Nogami, Naoyuki
Department of Respiratory Medicine, NHO Shikoku Cancer Center
Hotta, Katsuyuki
Department of Respiratory Medicine, Okayama University Hospital
Kaken ID
publons
researchmap
Kuyama, Shoichi
Department of Medicine, Chugoku Central Hospital
Kiura, Katsuyuki
Department of Respiratory Medicine, Okayama University Hospital
ORCID
Kaken ID
publons
researchmap
Takigawa, Nagio
Department of Respiratory Medicine, Okayama University Hospital
Chikamori, Kenichi
Department of Respiratory Medicine, NHO Yamaguchi-Ube Medical Center
Shibayama, Takuo
Department of Medicine, NHO Minami-Okayama Medical Center
Kishino, Daizo
Department of Respiratory Medicine, NHO Yamaguchi-Ube Medical Center
Hosokawa, Shinobu
Department of Respiratory Medicine, Okayama Red Cross Hospital
Tamaoki, Akihiko
Department of Respiratory Medicine, Okayama Institute of Health and Prevention
Harita, Shingo
Department of Medicine, Chugoku Central Hospital
Tabata, Masahiro
Department of Respiratory Medicine, Okayama University Hospital
Kaken ID
researchmap
Ueoka, Hiroshi
Department of Respiratory Medicine, NHO Yamaguchi-Ube Medical Center
Shinkai, Tetsu
Department of Respiratory Medicine, NHO Shikoku Cancer Center
Tanimoto, Mitsune
Department of Respiratory Medicine, Okayama University Hospital
Kaken ID
publons
researchmap
|
抄録 | Backgrounds: Chemotherapy is a mainstay in the treatment of extensive-disease small-cell lung cancer (ED-SCLC), although the survival benefit remains modest. We conducted a phase II trial of amrubicin (a topoisomerase II inhibitor) and topotecan (a topoisomerase I inhibitor) in chemotherapy-naïve and relapsed SCLC patients. Methods: Amrubicin (35 mg/m(2)) and topotecan (0.75 mg/m(2)) were administered on days 3-5 and 1-5, respectively. The objective response rate (ORR) was set as the primary endpoint, which was assessed separately in chemotherapy-naïve and relapsed cases. Results: Fifty-nine patients were enrolled (chemotherapy-naïve 31, relapsed 28). The ORRs were 74% and 43% in the chemotherapy-naïve and relapsed cases, respectively. Survival data were also promising, with a median progression-free survival time and median survival time of 5.3 and 14.9 months and 4.7 and 10.2 months in the chemotherapy-naïve and relapsed cases, respectively. Even refractory-relapsed cases responded to the treatment favorably (27% ORR). The primary toxicity was myelosuppression with grades 3 or 4 neutropenia in 97% of the patients, which led to grades 3 or 4 febrile neutropenia in 41% of the patients and two toxic deaths. Conclusion: This phase II study showed the favorable efficacy and moderate safety profiles of a topotecan and amrubicin two-drug combination especially in relapsed patients with ED-SCLC.
|
キーワード | Lung cancer
Topotecan
Amrubicin
Chemo-naive
Sensitive relapse
Refractory relapse
|
発行日 | 2011-10
|
出版物タイトル |
Lung Cancer
|
巻 | 74巻
|
号 | 1号
|
出版者 | Elsevier Ireland Ltd.
|
開始ページ | 80
|
終了ページ | 84
|
ISSN | 0169-5002
|
NCID | AA10785743
|
資料タイプ |
学術雑誌論文
|
言語 |
英語
|
著作権者 | © 2011 Elsevier Ireland Ltd. All rights reserved.
|
論文のバージョン | author
|
査読 |
有り
|
DOI | |
PubMed ID | |
Web of Science KeyUT |